Managing Brain Metastases: Neuropsychological Testing and Biomarkers
Author Information
Author(s): Andrew Baschnagel, Wolters Pamela L, Kevin Camphausen
Primary Institution: National Cancer Institute, National Institutes of Health
Hypothesis
Neuropsychological testing and biomarkers can help optimize therapies for patients with brain metastases.
Conclusion
Whole brain radiation therapy is the standard treatment for brain metastases, but it carries risks of neurocognitive impairment.
Supporting Evidence
- Brain metastases occur in 10-30% of adult cancer patients.
- Whole brain radiation therapy can improve survival from 1 month to 3-6 months.
- Neuropsychological tests can help assess cognitive function in patients with brain metastases.
Takeaway
Doctors use special tests to check how well the brain is working in patients with brain tumors, which helps them choose the best treatments.
Methodology
The study reviews current management strategies for brain metastases and discusses the use of neuropsychological tests and biomarkers.
Potential Biases
Potential biases may arise from the selection of studies reviewed and the interpretation of their results.
Limitations
The study primarily focuses on existing literature and may not include all recent advancements in treatment.
Participant Demographics
The study includes adult cancer patients with brain metastases, primarily from lung, breast, and melanoma origins.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website